Is This a 737 Max Moment for Brolucizumab?

Philip J. Rosenfeld; David J. Browning

doi:10.1016/j.ajo.2020.05.012

Is This a 737 Max Moment for Brolucizumab?

Philip J. Rosenfeld, David J. Browning

Ophthalmology

Research output: Contribution to journal › Editorial › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	A7-A8
Journal	American journal of ophthalmology
Volume	216
DOIs	https://doi.org/10.1016/j.ajo.2020.05.012
State	Published - Aug 2020

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ajo.2020.05.012

Cite this

@article{d4cdac50c87248a897787ec05eae0cd2,

title = "Is This a 737 Max Moment for Brolucizumab?",

author = "Rosenfeld, {Philip J.} and Browning, {David J.}",

note = "Funding Information: Funding/Support: No funding or grant support. Financial Disclosures: Philip Rosenfeld receives research support from Carl Zeiss Meditec, Inc, and Stealth BioTherapeutics. He is also a consultant for Apellis, Biogen, Boehringer-Ingelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotech, EyePoint, Ocunexus Therapeutics, Ocudyne, and Unity Biotechnology. Philip Rosenfeld has equity interest in Apellis, Valitor, Verana Health, and Ocudyne. David Browning receives research support from the DRCR Retina.net and Regeneron. He has an equity interest in Zeiss-Meditec. He receives royalties from Springer Inc. Prashanth Iyer, MD provided valuable background research support for this Editorial. All authors attest that they meet the current ICMJE criteria for authorship.",

year = "2020",

month = aug,

doi = "10.1016/j.ajo.2020.05.012",

language = "English (US)",

volume = "216",

pages = "A7--A8",

journal = "American Journal of Ophthalmology",